Advertisement

Topics

F16IL2 Plus Doxorubicin in Solid Tumour Patients

2014-08-27 03:13:22 | BioPortfolio

Summary

This Phase Ib/II study is an openlabel, multicenter study for patients with solid tumors and breast cancer amenable to anthracyclin therapy.

The study is divided in two parts:

Phase I: an open-label, dose escalation study of F16IL2 in combination with doxorubicin for patients with solid tumors.

Phase II: a prospective, single-arm, multicentre study of a fixed dose of F16IL2 in combination with doxorubicin, equivalent to stage 1 of the Simon two-stage phase II design, for patients with breast cancer amenable to anthracyclin therapy.

Description

F16IL2 is a recombinant fusion protein composed of a fully human recombinant monoclonal antibody (F16), and human recombinant interleukin-2 (IL-2).

Tenascin - C (TN-C) is an extracellular matrix glycoprotein whose overexpression is associated with neoplastic tissues. The protein is coded by a single gene and it's expression is regulated by a single promoter (Carnemolla et al 1999). Structurally different isoforms are generated by alternative splicing of the TN-C transcript and splice variants, normally absent in adult tissues, become more predominant and over expressed in cancer stroma (Takatsugu et al (2003). The large isoform of Tenascin - C represents probably the best tumour-associated antigen of breast cancer described so far. Research performed by various independent groups has shown that large TN-C variants are preferentially expressed in breast cancer tissues and that they are closely associated with the migration and proliferation of breast cancer cells. ScFv(F16) is a human recombinant antibody fragment in the scFv (single chain Fragment variable) format that is directed against tenascin C, an angiogenesis marker common to most solid tumors independent of the tumor type. ScFv(F16) selectively localizes in tumor tissues in animal models as demonstrated both histologically and during mechanistic studies involving mice transfected with orthotopic human tumours.

IL2, the human cytokine interleukin-2, is a potent stimulator of the immune response. It has a central role in the regulation of T cell responses and effects on other immune cells such as natural killer cells, B cells, monocyte/macrophages and neutrophils (Smith, 1988). IL2 can induce tumor regression through its ability to stimulate a potent cell-mediated immune response in vivo (Rosenberg, 2000).

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Advanced Solid Tumor

Intervention

F16IL2 in combination with doxorubicin

Location

A.O. UNIVERSITARIA OSPEDALI RIUNITI - OSPEDALE UMBERTO I DI ANCONA - ANCONA (AN) (Italy)
Ancona
Italy
20141

Status

Recruiting

Source

Philogen S.p.A.

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:13:22-0400

Clinical Trials [4208 Associated Clinical Trials listed on BioPortfolio]

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Phase Ib study of the tumor-targeting human L19TNFα monoclonal antibody-cytokine fusion protein in combination with doxorubicin in patients with advanced solid tumors. This study foresee...

F16IL2 Plus Paclitaxel in Solid Tumour Patients

This Phase Ib/II study is an open label, multicenter study for patients with solid tumors and breast cancer amenable to taxane therapy. The study is divided in two parts: Phase I: ...

PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining PS-3...

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Ph...

Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors

RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin, work in different ways to ...

PubMed Articles [12510 Associated PubMed Articles listed on BioPortfolio]

GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.

Ovarian cancer as a recurrent disease is often refractory to treatment including pegylated liposomal doxorubicin hydrochloride (Lipo-Dox). Here, GE11 peptide-modified reversibly crosslinked polymersom...

Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) - A systematic review and meta-analysis.

Despite a lack of improvement in overall survival (OS) with doxorubicin-based combinations over doxorubicin alone in advanced STS, the role of multi-agent chemotherapy remains poorly defined.

Intelligent Albumin-MnONanoparticles as pH-/HO-Responsive Dissociable Nanocarriers to Modulate Tumor Hypoxia for Effective Combination Therapy.

Sildenafil Citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer.

Sildenafil is an approved drug for the treatment of erectile dysfunction. The drug exerts its action through the relaxation of smooth muscles and the modulation of vascular endothelial permeability. I...

Spatiotemporal Control of Doxorubicin Delivery from "Stealth-Like" Prodrug Micelles.

In the treatment of cancer, targeting of anticancer drugs to the tumor microenvironment is highly desirable. Not only does this imply accurate tumor targeting but also minimal drug release en route to...

Medical and Biotech [MESH] Definitions

A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.

A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)

Mucocellular carcinoma of the ovary, usually metastatic from the gastrointestinal tract, characterized by areas of mucoid degeneration and the presence of signet-ring-like cells. It accounts for 30%-40% of metastatic cancers to the ovaries and possibly 1%-2% of all malignant ovarian tumors. The lesions may not be discovered until the primary disease is advanced, and most patients die of their disease within a year. In some cases, a primary tumor is not found. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1685)

A solid tumor consisting of a dense infiltration of MAST CELLS. It is generally benign.

Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.

More From BioPortfolio on "F16IL2 Plus Doxorubicin in Solid Tumour Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Searches Linking to this Trial